The so-called DeepTEPP (Deep-learning-based Treatment Effectiveness and Prognosis Predictor) network could not only predict disease outcomes, but also predict adjuvant anti-HER2 treatment effectiveness, thus to guide anti-HER2 targeted treatment strategy in early HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.